Sugi Predict

Sugi Predict / Compounds / SCHEMBL16533554

SCHEMBL16533554

SCHEMBL16533554

C/C(=N/[S+]([O-])C(C)(C)C)c1cc(Cl)nc(-c2ccc(F)cc2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.38
▸ GAA P10253 2/20 0.38
▸ ADORA2A P29274 3/20 0.36
▸ ADORA3 P0DMS8 2/20 0.36
▸ MAPT P10636 4/20 0.36
▸ KDM4E B2RXH2 4/20 0.36
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ TP53 P04637 2/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ S1PR2 O95136 1/20 0.36
▸ NPC1 O15118 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ NFKB1 P19838 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ RECQL P46063 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ NFKB2 Q00653 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18031526 1.00 LMNA (0.38) LMNAGAAADORA2AADORA3MAPT
SCHEMBL16533634 0.87 ABL1 (0.38) MAPTPTGS2MAPK1
SCHEMBL18031391 0.83 VCP (0.35) LMNAGAAADORA2AADORA3MAPT
SCHEMBL19853121 0.81 KDM4C (0.40) LMNAGAAADORA2AADORA3MAPT
SCHEMBL17981994 0.81 KDM4C (0.40) LMNAGAAADORA2AADORA3MAPT
SCHEMBL18019671 0.81 KDM4C (0.40) LMNAGAAADORA2AADORA3MAPT
SCHEMBL19837724 0.81 KDM4C (0.40) LMNAGAAADORA2AADORA3MAPT
SCHEMBL23493183 0.76 LMNA (0.43) LMNAGAAMAPTKDM4ESMN1; SMN2
SCHEMBL20449205 0.76 LMNA (0.43) LMNAGAAMAPTKDM4ESMN1; SMN2
SCHEMBL20528387 0.76 LMNA (0.43) LMNAGAAMAPTKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11021444-B2 Antiviral compounds Janssen Biopharma, Inc. (US) 2021-06-01 — — US disclosed
US-20190263754-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. (US) 2019-08-29 — — US disclosed
US-20180065932-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. 2018-03-08 — — US disclosed
US-20180065932-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. 2018-03-08 — — US disclosed
US-20150065504-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. 2015-03-05 — — US disclosed
US-20150065504-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. 2015-03-05 — — US disclosed
WO-2015026792-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. (US) 2015-02-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190263754-A1 ANTIVIRAL COMPOUNDS MAVS, SARS1, ZC3HAV1 LMNA 2978/4885GAA 236/4885ADORA2A 1916/4885
US-11021444-B2 Antiviral compounds MAVS, SARS1, ZC3HAV1 LMNA 2978/4885GAA 236/4885ADORA2A 1916/4885
US-20180065932-A1 ANTIVIRAL COMPOUNDS MAVS, SARS1, ZC3HAV1 LMNA 2978/4885GAA 236/4885ADORA2A 1916/4885
US-20150065504-A1 ANTIVIRAL COMPOUNDS MAVS, SARS1, ZC3HAV1 LMNA 2978/4885GAA 236/4885ADORA2A 1916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.